“Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s299. doi:10.25251/skin.7.supp.299.